Bullish Case: ALEC’s mean-reverting behavior and the Helium price-density curve assign meaningful weight to $1.5–$2.5 rather than collapse. A credible AL137 IND/PK or BBB-shuttle partnership before the January 2, 2027 GSK termination could expose platform value and trigger a nonlinear re-rating. The 23% rebound shows reflexive upside, although exceptionally illiquid options make apparent convexity unreliable.

Bearish Case: Two sortilin/progranulin failures, GSK’s pending exit, continuing losses, and possible financing needs leave ALEC without a validated clinical program. The historical-return surface visibly extends toward severe negative long-horizon outcomes, while put IV above 150% and sparse quotes signal both downside concern and poor price discovery. Earlier bearish direction was broadly right, but timing overstated: the stock rebounded 23% instead of immediately drifting lower.

Potential Outcomes:

• 45% $1.0–$1.7 rangebound/dilution; falsified by sustained close above $2.5 or major financing.
• 25% $0.7–$1.1 on runway/IND slippage or going-concern language.
• 20% $1.6–$2.5 on credible AL137 data or IND filing by year-end.
• 10% above $3 on licensing/acquisition.

Oracle: asymmetric, event-dependent optionality; extreme IV and illiquidity weaken precision. Earlier calls correctly identified biology and financing risk, but overestimated near-term downside. Helium’s +2.27% signal is weakly supported (historical correlation −0.2).

August 18, 2026